menu
    • menu
    [{"orgOrder":0,"company":"Glytherix","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"177-Lu DOTA Miltuximab","moa":"GPC1","graph1":"Oncology","graph2":"Phase I","graph3":"Glytherix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glytherix \/ SHINE Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Glytherix \/ SHINE Technologies"},{"orgOrder":0,"company":"Glytherix","sponsor":"Nusano","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"177-Lu","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Glytherix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glytherix \/ Glytherix","highestDevelopmentStatusID":"4","companyTruncated":"Glytherix \/ Glytherix"}]

    Find Clinical Drug Pipeline Developments & Deals by Glytherix

    Menu

    Glytherix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glytherix

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Glytherix

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glytuzumab,177-Lu

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Nusano

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nusano and GlyTherix Announce Lutetium-177 Supply Agreement

                            Details : Under the agreement, GlyTherix's will focus on the radiotherapy approach that combines Lu-177 with an antibody Glytuzumab targeting Glypican-1, a protein found in aggressive cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Glytuzumab,177-Lu

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Nusano

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Glytherix

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Glytherix

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA Miltuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GlyTherix Partners with SHINE Technologies For Radiotherapy in Aggressive Cancers

                            Details : Under the terms of agreement, SHINE will supply its n.c.a. Lu-177 chloride, Ilumira, for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : 177-Lu DOTA Miltuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : SHINE Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth